Nutmeg Oil and Medications: What the Evidence Does Not Show

If you take a prescription medicine, particularly one that acts on the brain or nervous system, the honest answer on nutmeg oil is that nobody has measured whether inhaling or skin-applying it changes how that medicine behaves, and absence of data is not evidence of no interaction. Our own safety copy goes further than the data: if you take medication acting on the central nervous system, do not use our nutmeg oil at all. This page sets out what the pharmacology literature does show, what kind of evidence it is, and what to hand a pharmacist.

Nutmeg Essential Oil bottle

Nutmeg Essential Oil

Our own Nutmeg Essential Oil, in sizes from 0.5 oz to bulk.

From $10.99

Shop Now →

What kind of evidence exists

A 2021 literature review of myristicin, the main nutmeg-oil constituent of interest (Seneme et al., Molecules, 2021), reports two enzyme findings. First, myristicin is "slightly capable of inhibiting" monoamine oxidase (MAO), the enzyme that breaks down serotonin and other neurotransmitters; the review says this could produce pro-serotonergic and cardiovascular effects. Second, it reports some inhibitory effect on the human liver enzymes CYP2E1, CYP2C19 and CYP1A2, strongest on CYP1A2. These enzymes clear many medicines from the body, so inhibiting one can in principle raise the level of a drug that depends on it.

Three limits apply to every one of those statements. The material is an isolated compound, not the oil and not the spice. The review does not say which findings came from test tubes, animals or people, so none can be read as a human result. And no route is attached: nothing in what was read connects these effects to the amount absorbed by breathing a diffuser or from a diluted skin product. The review names no specific drug interactions.

The wider picture is just as thin. A 2023 laboratory study of lavender oil (Mondal et al., Molecules, 2023) states that there has been no systematic evaluation of how its main components inhibit or induce CYP enzymes, and that relatively few human clinical drug-interaction studies have been done on essential oils generally. That is a different oil, so it is evidence about the field and not about nutmeg, but it shows that "no interaction reported" usually means "not studied".

The only human data point, and what it does not show

The Illinois Poison Center's review of nutmeg exposures from 2001 to 2011 (Ehrenpreis et al., J Med Toxicol, 2014) found 32 cases, aged 2 to 30. Of the 15 intentional ingestions, five involved other drugs taken at the same time. The most serious case was a 16-year-old who needed a ventilator for about 24 hours after taking nutmeg together with duloxetine, clonazepam, K2 and acetaminophen in a suicide attempt. The paper does not say whether any exposure was to the oil, and it cannot separate the effect of nutmeg from the effect of the other drugs. It is a warning about mixing, not an interaction measurement. Spice-ingestion cases also say nothing direct about a few drops in a diffuser.

Why our copy says "do not use" and the data says "unknown"

These two statements are not in conflict. When a material has documented MAO and CYP activity in isolation, a documented intoxication profile when swallowed, and no human data for inhalation, a seller's cautious rule is to exclude the people most likely to be harmed by being wrong. The review puts neuropsychological symptoms at 10 to 15 g of nutmeg, "or about 400 mg of myristicin" (6 to 7 mg/kg), after swallowing. For scale only: EFSA's analysis of seven Indonesian nutmeg oil batches found myristicin at 8.3 to 10.7% (EFSA, 2023). A half-ounce bottle holds about 13.1 g of oil (0.5 oz at the 0.887 relative density on our published COA batch), so at that composition it would hold roughly 1.1 to 1.4 g of myristicin, about 2.7 to 3.5 times the review's 400 mg. That is composition from other batches, not a figure for our oils, and swallowing is never the use. It shows why the bottle belongs out of reach, and why the tiny skin and air doses in the rest of this page are a separate question.

The skin number: where our 0.5% to 2% copy meets a published limit

Our product pages say to dilute to 0.5% to 2% in a carrier oil and patch test first. Before repeating that for anyone, the published limits were checked. The International Fragrance Association's Standards (51st Amendment, January 2024) have no entry for nutmeg oil; a text search of the compilation found no "nutmeg" or "Myristica" in it. They do, however, restrict the constituents. Under the Safrole, Isosafrole and Dihydrosafrole standard (published 1987), natural extracts containing safrole are accepted only if the total of those three in the finished consumer product does not exceed 0.01%, with carcinogenicity as the driver. The same compilation limits methyl eugenol by product category, from 0.000069% to 0.066%.

The arithmetic uses EFSA's seven batches, which held 1.69 to 2.30% safrole:

Oil in the carrierSafrole delivered (at 1.69% to 2.30% in the oil)Against IFRA's 0.01%
0.5%0.0085% to 0.0115%Straddles the line
1%0.017% to 0.023%About 1.7 to 2.3 times over
2%0.034% to 0.046%About 3.4 to 4.6 times over

Put the other way, 0.01% safrole is reached at about 0.43% oil (at 2.30% safrole) to 0.59% (at 1.69%). The methyl eugenol standard points the same direction: for the category with a 0.0015% limit (Category 5A; the category definitions are in IFRA's own guidance and were not read here), EFSA's top figure of 0.33% methyl eugenol gives an oil ceiling of about 0.45%. These are derived numbers, inference from two documents, not a published nutmeg limit, and they assume an oil of EFSA's composition. We hold no constituent figure for our oils.

What the numbers mean for our copy: the top of our 0.5% to 2% range sits at several times the figure those standards imply. Our recommendation is to treat 0.5% as the ceiling, which is roughly 3 drops per ounce of carrier by the arithmetic on our COA density, and to skip skin use altogether if you take a nervous-system medicine, are pregnant or nursing, or are choosing for a child. The Tisserand Institute does not settle this: its nutmeg post says diluted topical use within its guidelines is acceptable and its chart of recommended topical maximums (an image on the same page, posted November 2019) gives East Indian nutmeg oil 0.8% for adults over 15, 0.2% in pregnancy and 0.2% for ages 6 to 15, and West Indian oil 5% for adults (Tisserand Institute, 2019); the chart says nothing about medicines. IFRA is an industry standard for fragrance in consumer products, not a law for a home massage oil, and a person asking about a medicine should treat it as one input for a pharmacist, not a verdict.

What to take to a pharmacist or prescriber

If anyone has swallowed the oil, call the Poison Help line, 1-800-222-1222 in the United States (poison.org). The ingestion page explains why swallowing is the route that matters most.

What this page does not say

It does not say nutmeg oil changes any medicine, and it does not say it is without effect. FDA treats products as drugs when their intended use is therapeutic (FDA, 2024), and we sell a fragrance material, so we offer no condition-specific advice. For pregnancy see the pregnancy page; for the general overview see the safety basics.

A neat bottle of nutmeg oil is a concentrated material with an unmeasured interaction profile; keep it capped, away from children, and out of your routine if any medicine on your list acts on the nervous system.

Nutmeg Essential Oil bottle

Nutmeg Essential Oil

Nutmeg Essential Oil from our own shop, in sizes from 0.5 oz to bulk.

From $10.99

Shop Now →

Sources & Further Reading